Repository logo
 
Publication

Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus

2020-12Journal article Open access
Simple item page
dc.contributor.authorPalma dos Reis, C
dc.contributor.authorCardoso, G
dc.contributor.authorCarvalho, C
dc.contributor.authorNogueira, I
dc.contributor.authorBorges, A
dc.contributor.authorSerrano, F
dc.date.accessioned2021-06-23T14:37:33Z
dc.date.available2021-06-23T14:37:33Z
dc.date.issued2020-12
dc.description.abstractSystemic lupus erythematosus (SLE) is a chronic, autoimmune disease associated with major obstetrical complications such as gestational loss, preterm delivery, fetal growth restriction (FGR) and preeclampsia. Published literature is not consensual regarding the main risk factors for each of these outcomes. Our goal with this study was to determine the most important predictors for each of the main adverse pregnancy outcomes in this population. We conducted a retrospective cohort study of unifetal pregnancies of women with the diagnosis of SLE followed in our unit between January 1994 and December 2016. We excluded elective terminations of pregnancy and cases lost to follow-up and we analyzed 157 pregnancies (128 women). Multiple logistic regression models for the outcomes gestational loss, preterm delivery, fetal growth restriction, and preeclampsia were built. Two-sided p-values of < 0.05 were used to determine statistical significance, and two-sided confidence intervals of 95% are reported. In our cohort, the main risk factors for gestational loss were maternal age and the presence of antiphospholipid antibodies. Lupic nephritis was predictive of a preterm delivery and preeclampsia. Renal involvement and lupus flares during pregnancy were risk factors for FGR. Overall, the main risk factor for an adverse pregnancy outcome were lupus flares during pregnancy. Despite optimal pregnancy monitoring, women with SLE are still at risk for adverse pregnancy outcomes. Risk stratification for each of these outcomes is crucial for an effective counselling and tailored monitoring.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationClin Rev Allergy Immunol. 2020 Dec;59(3):287-294.pt_PT
dc.identifier.doi10.1007/s12016-019-08762-9pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3742
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.subjectMAC GINpt_PT
dc.subjectMAC MEDpt_PT
dc.subjectAdultpt_PT
dc.subjectAntibodies, Antiphospholipid / bloodpt_PT
dc.subjectAntibodies, Antiphospholipid / immunologypt_PT
dc.subjectAutoimmunitypt_PT
dc.subjectBiomarkerspt_PT
dc.subjectFemalept_PT
dc.subjectHumans
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFetal Growth Retardation / diagnosis
dc.subjectFetal Growth Retardation / etiology
dc.subjectLupus Erythematosus, Systemic / diagnosis
dc.subjectLupus Erythematosus, Systemic / epidemiology
dc.subjectLupus Erythematosus, Systemic / immunology
dc.subjectMiddle Aged
dc.subjectPre-Eclampsia / diagnosis
dc.subjectPre-Eclampsia / etiology
dc.subjectYoung Adult
dc.subjectPregnancy
dc.subjectPregnancy Complications / diagnosis
dc.subjectPregnancy Complications / epidemiology*
dc.subjectPregnancy Outcome / epidemiology*
dc.subjectRetrospective Studies
dc.titlePrediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosuspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage294pt_PT
oaire.citation.issue3pt_PT
oaire.citation.startPage287pt_PT
oaire.citation.titleClinical Reviews in Allergy & Immunologypt_PT
oaire.citation.volume59pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clin Rev Allergy Immunol 2020 287.pdf
Size:
319.59 KB
Format:
Adobe Portable Document Format
Download

Collections

GIN - Artigos
MED - Artigos